Bevacizumab

Basic Information

  • CAS No.: 216974-75-3
  • Purity: 99%
Inquiry

Details

Quality products?make an important contribution to long-term revenue and profitability. High Quality Chinese Factory supply 216974-75-3 Bevacizumab

1.What is the Avastin ?

Bevacizumab, a humanized IgG1 monoclonal antibody against vascular endothelial growth factor (VEGF), inhibits tumor angiogenesis and delays disease progression. It was launched in the US as an intravenous infusion for the treatment of metastatic colorectal cancer in combination with fluorouracil-based chemotherapy. Bevacizumab was developed by engineering the VEGF binding residues of the murine neutralizing antibody A.4.6.1 into the framework of the consensus human IgG1. Its amino acid sequence is approximately 93% human IgG and 7% murine antibody and is produced in a CHO cell expression system. Bevacizumab binds VEGF with high affinity (Kd=0.5 nM) and prevents its interaction with tyrosine kinase receptors VEGFR1 and VEGFR2 on the surface of endothelial cells, thereby inhibiting cell proliferation and microvascular growth. In mouse models, administration of bevacizumab blocked the growth of human tumor xenografts and reduced the size and number of metastases. The recommended dosage of bevacizumab is 5 mg/kg administered once every 2 weeks as an intravenous infusion until disease progression is detected. Based on a population pharmacokinetic analysis of patients who received 1–20 mg/kg of bevacizumab once every 1–3 weeks, the estimated half-life was approximately 20 days, and the predicted time to reach steady state was 100 days. The maximum and minimum steady-state serum concentrations at 2.5 mg/kg/week dose were 226 and 88 μg/mL, respectively. Clearance of bevacizumab is low, and varies with body weight, gender and tumor burden. In patients with colorectal cancer receiving bevacizumab 5–10 mg/kg in combination with fluorouracil and leucovorin, mean total clearance was 2.79 ml/kg/day. In clinical studies involving the administration of bevacizumab (5 mg/kg every 2 weeks) or placebo in addition to bolus-IFL (irinotecan 125 mg/m2 i.v., 5-fluorouracil 500 mg/ m2 i.v., and leucovorin 20 mg/m2 i.v. administered once weekly for four weeks every six weeks), the median overall survival was significantly increased from 15.6 months in the bolus IFL + placebo arm to 20.3 months in the bolus IFL + bevacizumab arm. Similar increases were also seen in progression-free survival (6.4 versus 10.6 months), overall response rate (35% versus 45%), and duration of response (7.1 months versus 10.4 months). The most common adverse events in these trials were hypertension, diarrhea and leucopenia. Other clinically significant adverse events reported occasionally were gastrointestinal perforations, thromboembolic events, bleeding and proteinuria. Because wound healing may be impaired by inhibition of VEGF, bevacizumab therapy is not recommended until 28 days after primary surgery.

2.What is the CAS number for Avastin ?

The CAS number of Avastin is 216974-75-3.

3.What are another words for Avastin ?

Synonyms?for?Avastin 216974-75-3:

4.What is Avastin (216974-75-3) used for?

Used in Oncology:
Avastin is used as an anticancer agent for various types of cancer. It is particularly effective against solid malignancies such as metastatic colorectal cancer, non-small cell lung cancer, renal cell carcinoma, and certain types of brain cancer. Avastin works by binding to VEGF with high affinity, preventing its interaction with tyrosine kinase receptors VEGFR1 and VEGFR2 on the surface of endothelial cells. This action inhibits cell proliferation and microvascular growth, blocking the growth of tumor xenografts and reducing the size and number of metastases.
Used in Combination Therapy:
Avastin is often used in combination with other chemotherapeutic drugs, such as fluorouracil and leucovorin, to enhance chemo-sensitivity and efficacy in resistant cases. This combination therapy has been shown to significantly increase median overall survival, progression-free survival, overall response rate, and duration of response in clinical studies.
Used in Intravenous Infusion:
The recommended dosage of Avastin is 5 mg/kg administered once every 2 weeks as an intravenous infusion until disease progression is detected. This method of administration ensures that the drug is directly introduced into the bloodstream, allowing for a controlled release and distribution throughout the body.
Used in Drug Delivery Systems:
To overcome the limitations of Avastin, such as low clearance and variability with body weight, gender, and tumor burden, novel drug delivery systems have been developed. These systems aim to improve the delivery, bioavailability, and therapeutic outcomes of the drug by employing various organic and metallic nanoparticles as carriers for Avastin delivery.
Brand name: Avastin

Relevant articles related to Avastin:

5.Buy Avastin with the best price .

KaiXin Chemicals Co.,Ltd is a quality supplier of Avastin. Our main goal is customer satisfaction. Contact us to negotiate the best price for your business on Avastin 216974-75-3.